Effect of isoprinosine on HIV antigenaemia

Lars Stubbe Teglbjærg, S Kroon, E Sandström, T Moestrup, B G Hansson, B F Vestergaard

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    Resumé

    OBJECTIVE: The objective of this study was to evaluate the effect of isoprinosine on HIV-antigen expression in HIV-positive patients without AIDS.

    DESIGN: Serum samples from anti-HIV-positive patients without AIDS participating in a double-blind, placebo-controlled trial of isoprinosine in the treatment of HIV infection were analysed for the presence of HIV antigen.

    SETTING: Data and samples were collected from the 21 medical centres who participated in the Scandinavian multicentre placebo-controlled isoprinosine study.

    PATIENTS, PARTICIPANTS: Samples were available from 19 of 21 participating centres. Of 866 patients who enrolled, baseline serum samples were available for 642 (74%; 308 isoprinosine- and 334 placebo-treated patients).

    INTERVENTIONS: Treatment was 1 g isoprinosine administered orally three times a day or matching placebo for 24 weeks.

    MAIN OUTCOME MEASURES: Comparison of HIV-antigen levels before and during treatment in both the isoprinosine-treated group and the placebo-treated group of patients.

    RESULTS: During the study, AIDS developed in 19 patients; 17 of whom were receiving placebo treatment and two isoprinosine. The proportion of HIV-antigen-positive patients developing AIDS during treatment was significantly different from the proportion of HIV-antigen-negative patients in whom AIDS developed (6 versus 2%; P = 0.02). No significant changes in HIV-antigen levels were observed between the isoprinosine- and the placebo-treated group of HIV-antigen-positive patients. Median HIV-antigen levels did not change significantly in either the isoprinosine- or the placebo-treated group.

    CONCLUSION: Our results suggest that isoprinosine does not have antiviral activity against HIV in vivo.

    OriginalsprogEngelsk
    TidsskriftAIDS
    Vol/bind6
    Udgave nummer2
    Sider (fra-til)199-201
    Antal sider3
    ISSN0269-9370
    StatusUdgivet - feb. 1992

    Fingeraftryk

    Inosine Pranobex
    HIV
    Placebos
    Acquired Immunodeficiency Syndrome
    Serum

    Citer dette

    Teglbjærg, L. S., Kroon, S., Sandström, E., Moestrup, T., Hansson, B. G., & Vestergaard, B. F. (1992). Effect of isoprinosine on HIV antigenaemia. AIDS, 6(2), 199-201.
    Teglbjærg, Lars Stubbe ; Kroon, S ; Sandström, E ; Moestrup, T ; Hansson, B G ; Vestergaard, B F. / Effect of isoprinosine on HIV antigenaemia. I: AIDS. 1992 ; Bind 6, Nr. 2. s. 199-201.
    @article{f1612278802f4a1088ab4a4b633193f6,
    title = "Effect of isoprinosine on HIV antigenaemia",
    abstract = "OBJECTIVE: The objective of this study was to evaluate the effect of isoprinosine on HIV-antigen expression in HIV-positive patients without AIDS.DESIGN: Serum samples from anti-HIV-positive patients without AIDS participating in a double-blind, placebo-controlled trial of isoprinosine in the treatment of HIV infection were analysed for the presence of HIV antigen.SETTING: Data and samples were collected from the 21 medical centres who participated in the Scandinavian multicentre placebo-controlled isoprinosine study.PATIENTS, PARTICIPANTS: Samples were available from 19 of 21 participating centres. Of 866 patients who enrolled, baseline serum samples were available for 642 (74{\%}; 308 isoprinosine- and 334 placebo-treated patients).INTERVENTIONS: Treatment was 1 g isoprinosine administered orally three times a day or matching placebo for 24 weeks.MAIN OUTCOME MEASURES: Comparison of HIV-antigen levels before and during treatment in both the isoprinosine-treated group and the placebo-treated group of patients.RESULTS: During the study, AIDS developed in 19 patients; 17 of whom were receiving placebo treatment and two isoprinosine. The proportion of HIV-antigen-positive patients developing AIDS during treatment was significantly different from the proportion of HIV-antigen-negative patients in whom AIDS developed (6 versus 2{\%}; P = 0.02). No significant changes in HIV-antigen levels were observed between the isoprinosine- and the placebo-treated group of HIV-antigen-positive patients. Median HIV-antigen levels did not change significantly in either the isoprinosine- or the placebo-treated group.CONCLUSION: Our results suggest that isoprinosine does not have antiviral activity against HIV in vivo.",
    keywords = "Acquired Immunodeficiency Syndrome, CD4-Positive T-Lymphocytes, Double-Blind Method, HIV Antigens, HIV Seropositivity, Humans, Inosine Pranobex, Leukocyte Count",
    author = "Teglbj{\ae}rg, {Lars Stubbe} and S Kroon and E Sandstr{\"o}m and T Moestrup and Hansson, {B G} and Vestergaard, {B F}",
    year = "1992",
    month = "2",
    language = "English",
    volume = "6",
    pages = "199--201",
    journal = "AIDS",
    issn = "0269-9370",
    publisher = "Lippincott Williams & Wilkins",
    number = "2",

    }

    Teglbjærg, LS, Kroon, S, Sandström, E, Moestrup, T, Hansson, BG & Vestergaard, BF 1992, 'Effect of isoprinosine on HIV antigenaemia', AIDS, bind 6, nr. 2, s. 199-201.

    Effect of isoprinosine on HIV antigenaemia. / Teglbjærg, Lars Stubbe; Kroon, S; Sandström, E; Moestrup, T; Hansson, B G; Vestergaard, B F.

    I: AIDS, Bind 6, Nr. 2, 02.1992, s. 199-201.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    TY - JOUR

    T1 - Effect of isoprinosine on HIV antigenaemia

    AU - Teglbjærg, Lars Stubbe

    AU - Kroon, S

    AU - Sandström, E

    AU - Moestrup, T

    AU - Hansson, B G

    AU - Vestergaard, B F

    PY - 1992/2

    Y1 - 1992/2

    N2 - OBJECTIVE: The objective of this study was to evaluate the effect of isoprinosine on HIV-antigen expression in HIV-positive patients without AIDS.DESIGN: Serum samples from anti-HIV-positive patients without AIDS participating in a double-blind, placebo-controlled trial of isoprinosine in the treatment of HIV infection were analysed for the presence of HIV antigen.SETTING: Data and samples were collected from the 21 medical centres who participated in the Scandinavian multicentre placebo-controlled isoprinosine study.PATIENTS, PARTICIPANTS: Samples were available from 19 of 21 participating centres. Of 866 patients who enrolled, baseline serum samples were available for 642 (74%; 308 isoprinosine- and 334 placebo-treated patients).INTERVENTIONS: Treatment was 1 g isoprinosine administered orally three times a day or matching placebo for 24 weeks.MAIN OUTCOME MEASURES: Comparison of HIV-antigen levels before and during treatment in both the isoprinosine-treated group and the placebo-treated group of patients.RESULTS: During the study, AIDS developed in 19 patients; 17 of whom were receiving placebo treatment and two isoprinosine. The proportion of HIV-antigen-positive patients developing AIDS during treatment was significantly different from the proportion of HIV-antigen-negative patients in whom AIDS developed (6 versus 2%; P = 0.02). No significant changes in HIV-antigen levels were observed between the isoprinosine- and the placebo-treated group of HIV-antigen-positive patients. Median HIV-antigen levels did not change significantly in either the isoprinosine- or the placebo-treated group.CONCLUSION: Our results suggest that isoprinosine does not have antiviral activity against HIV in vivo.

    AB - OBJECTIVE: The objective of this study was to evaluate the effect of isoprinosine on HIV-antigen expression in HIV-positive patients without AIDS.DESIGN: Serum samples from anti-HIV-positive patients without AIDS participating in a double-blind, placebo-controlled trial of isoprinosine in the treatment of HIV infection were analysed for the presence of HIV antigen.SETTING: Data and samples were collected from the 21 medical centres who participated in the Scandinavian multicentre placebo-controlled isoprinosine study.PATIENTS, PARTICIPANTS: Samples were available from 19 of 21 participating centres. Of 866 patients who enrolled, baseline serum samples were available for 642 (74%; 308 isoprinosine- and 334 placebo-treated patients).INTERVENTIONS: Treatment was 1 g isoprinosine administered orally three times a day or matching placebo for 24 weeks.MAIN OUTCOME MEASURES: Comparison of HIV-antigen levels before and during treatment in both the isoprinosine-treated group and the placebo-treated group of patients.RESULTS: During the study, AIDS developed in 19 patients; 17 of whom were receiving placebo treatment and two isoprinosine. The proportion of HIV-antigen-positive patients developing AIDS during treatment was significantly different from the proportion of HIV-antigen-negative patients in whom AIDS developed (6 versus 2%; P = 0.02). No significant changes in HIV-antigen levels were observed between the isoprinosine- and the placebo-treated group of HIV-antigen-positive patients. Median HIV-antigen levels did not change significantly in either the isoprinosine- or the placebo-treated group.CONCLUSION: Our results suggest that isoprinosine does not have antiviral activity against HIV in vivo.

    KW - Acquired Immunodeficiency Syndrome

    KW - CD4-Positive T-Lymphocytes

    KW - Double-Blind Method

    KW - HIV Antigens

    KW - HIV Seropositivity

    KW - Humans

    KW - Inosine Pranobex

    KW - Leukocyte Count

    M3 - Journal article

    VL - 6

    SP - 199

    EP - 201

    JO - AIDS

    JF - AIDS

    SN - 0269-9370

    IS - 2

    ER -

    Teglbjærg LS, Kroon S, Sandström E, Moestrup T, Hansson BG, Vestergaard BF. Effect of isoprinosine on HIV antigenaemia. AIDS. 1992 feb;6(2):199-201.